

Yuri Frederik van der Heijden, MD, MPH

PERSONAL INFORMATION

Office Address:	Vanderbilt University 1161 21 st Avenue South, A2200 MCN Nashville, TN 37232-2582 USA	The Aurum Institute 29 Queens Road Parktown, Johannesburg 2193 South Africa
Office Phone:	+1 (615) 322-2035	+27 (0) 10 590 1300
Office Fax:	+1 (615) 343-6160	
Pager:	+1 (615) 835-5086	
Email Address:	yuri.vanderheijden@vumc.org	yvanderheijden@auruminstitute.org

Personal Data

Date and Place of Birth: March 26, 1979, Atlanta, Georgia, USA

Languages: English: fluent; speaking, reading, writing
Dutch: fluent; speaking, reading, writing
French: moderate proficiency; speaking, reading, writing
Spanish: conversational; speaking, reading

EDUCATION

Sep. 1997-June 2001 Bachelor of Science, Biology
Furman University
Greenville, SC

August 2001-May 2005 Doctor of Medicine
Vanderbilt University School of Medicine
Nashville, TN

POST-GRADUATE TRAINING

July 2005-June 2008 Residency in Internal Medicine
Vanderbilt University Medical Center
Nashville, TN

July 2009-June 2012 Fellowship in Infectious Diseases
Vanderbilt University Medical Center
Nashville, TN

July 2011-June 2013 Chief Fellow, Infectious Diseases
Vanderbilt University Medical Center
Nashville, TN

Sep. 2012-May 2014 Master of Public Health
Vanderbilt University School of Medicine
Nashville, TN

LICENSURE AND BOARD CERTIFICATION

December 2007-present Tennessee Medical License; #43209
August 2008-present Diplomate in Internal Medicine
American Board of Internal Medicine
October 2011-present Diplomate in Infectious Diseases
American Board of Internal Medicine

HONORS/AWARDS

1997-2001 Founder's Scholarship
Furman University
Greenville, SC
1999-2001 Furman Bisher Scholarship Award
Furman University
Greenville, SC
2001 Verizon Academic All-American, Third Team
Furman University
Greenville, SC
2001 Dave Hart Southern Conference Postgraduate Scholarship
Furman University
Greenville, SC
2005 The George and Barbara Burns Medical Missions Award
Vanderbilt University School of Medicine
Nashville, TN
2012-2014 Vanderbilt University Master of Public Health Program Goldberger
Scholarship (full tuition)
2012-2017 National Institutes of Health Clinical Research Loan Repayment
Program
2013 Outstanding Clinical Fellow in Infectious Diseases
Vanderbilt University
2014 Vanderbilt Physician Scientist Development (VPSD) Program
Award

EMPLOYMENT

August 2008-June 2009 Hospitalist
St. Thomas Hospital
Nashville, TN, August

July 2010-June 2012	Part-time Physician Vanderbilt International Travel Medicine Clinic Nashville, TN
July 2010-June 2013	Part-time Physician, Hospitalist St. Thomas Hospital Nashville, TN
July 2013-Sep. 2014	Instructor, Department of Medicine Vanderbilt University Medical Center Nashville, TN
October 2014-present	Assistant Professor, Department of Medicine Vanderbilt University Medical Center Nashville, TN
May 2019-present	Senior Researcher The Aurum Institute Johannesburg, South Africa

PROFESSIONAL ORGANIZATIONS

2002-2005	Vanderbilt Microbes and Defense Academic Honor Society
2009, 2017-present	Infectious Diseases Society of America
2010, 2017-2019	American Thoracic Society
2012-present	International Union Against Tuberculosis and Lung Disease

PROFESSIONAL ACTIVITIES

Intramural:

July 2003-May 2004	Third Year Class President, Class of 2005 Vanderbilt University School of Medicine
June 2004-May 2005	Curriculum Committee, Fourth Year Class Representative Vanderbilt University School of Medicine
July 2012-June 2013	House Staff Advisory Council Vanderbilt University Medical Center
July 2012-June 2013	Infectious Diseases Fellowship Program Planning Committee Vanderbilt University Medical Center
July 2012-June 2013	Division of Infectious Diseases Education Committee Vanderbilt University Medical Center

September 2014 Vanderbilt Institute for Research Development & Ethics (VIRDE),
Mock Study Reviewer, Vanderbilt Institute for Global Health

August 2017-present Infectious Diseases Research Operations Committee (IDROC)
Vanderbilt University Medical Center

Extramural:

Dec. 2018-Nov. 2019 AIDS Clinical Trials Group (ACTG) Tuberculosis Transformative
Science Group, Member-in-Training

December 2019-present AIDS Clinical Trials Group (ACTG) Tuberculosis Transformative
Science Group, Member

Peer review activities:

2011, 2018 International Journal of Tuberculosis and Lung Disease

2013, 2015, 2016 Antimicrobial Agents and Chemotherapy

2014 Journal of Antimicrobial Chemotherapy

2014 Clinical Medicine & Research

2014, 2015 PLOS ONE

2015 European Respiratory Journal

2015 Public Health Reports

2017 Journal of Epidemiology and Global Health

2018 American Journal of Epidemiology

2019 New England Journal of Medicine (co-reviewer)

2020, 2021 BMC Infectious Diseases

International Experience:

June 2000 International Volunteer Experience
Onze Lieve Vrouw Gasthuis (Hospital)
Amsterdam, The Netherlands

June-July 2000 International Volunteer Program
Centre Hospitalier de Troyes (Hospital)
Troyes, France

June 2002	Summer Medical Institute Mobile Medical Mission Small Group Leader Cusco, Peru
June 2003	Summer Medical Institute Mobile Medical Mission Student Team Leader Cusco, Peru
June 2004	Summer Medical Institute Mobile Medical Mission Return Training Leader Cusco, Peru
February 2005	Manna Mission Hospital Fourth Year Medical Student Rotation Teshie-Nungua, Ghana
June 2008	Summer Medical Institute Mobile Medical Mission Team Leader Accra, Ghana
June 2009	Summer Medical Institute Mobile Medical Mission Project Director Accra, Ghana
Aug. 2012, May 2014, Nov. 2014, Mar. 2015, Sep. 2015, Sep. 2016, Dec. 2016, Feb. 2017, Jun. 2017, Sep. 2017, Nov. 2017, Feb. 2018, Jun. 2018, Sep. 2018, Dec. 2018, Jul. 2019, Nov. 2019	Research Trips University of Cape Town and Stellenbosch University Cape Town, South Africa
October 2015-July 2016	Relocation to Cape Town, South Africa for work on K08 studies
Jun. 2013, Jan. 2014, Jun. 2016, Nov. 2017, Jun. 2018	Research Trips, Africa Health Research Institute (AHRI) Durban, South Africa
Sep. 2017	RePORT International Annual Meeting Rapporteur Rio de Janeiro, Brazil
Jun. 2018, Sep. 2018, Jun. 2019, Sep. 2019, Nov. 2019, Feb. 2020	Research Trips, The Aurum Institute Johannesburg, South Africa
August 2019	Medical Service Trip, Clinician and Student Mentor Managua, Nicaragua

Other Professional Activities:

Summer 1999	Centers for Disease Control and Prevention Office on Smoking and Health Summer Research Internship Atlanta, Georgia
August 2002-July 2003	Vanderbilt University School of Medicine International Health Committee Foreign Student Host Nashville, TN
August 2004	Vanderbilt University School of Medicine Cal Turner Program for Moral Leadership Medical School Representative Nashville, TN
July 2009-June 2010	Vanderbilt University School of Medicine Quality Improvement Project: “Incidence of Acute Kidney Injury Following Placement of Antibiotic-Impregnated Cement Spacers: A Retrospective Review” Nashville, TN
July 2010-June 2011	Vanderbilt University School of Medicine Quality Improvement Project: “Reducing Medical Errors in Transitions of Care from Vanderbilt University Medical Center to the Vanderbilt Comprehensive Care Center” Nashville, TN
August, November 2011	Siloam Medical Outreach Medical Clinic for Burmese Refugees, Physician Volunteer, Smyrna, TN
May-November 2018	Siloam Health Nashville Neighbors Program Refugee Family Health and Safety Education, Volunteer Nashville, TN
July 2018	Health Fair in coordination with Siloam Health Volunteer Clinic and Community Health Assessment for Refugees from Central Africa, Director Nashville, TN

TEACHING ACTIVITIES**Mentorship:**

2017-2018	Adoma Manful, Master of Public Health Thesis Mentor
2016-present	Farina Karim, study coordinator at Africa Health Research Institute

October 2019 Maryam Amour, Vanderbilt Institute for Research Development & Ethics (VIRDE), Faculty Mentor, Vanderbilt Institute for Global Health

October 2019 Benson Kidenya, Vanderbilt Institute for Research Development & Ethics (VIRDE), Faculty Mentor, Vanderbilt Institute for Global Health

Medical School Courses:

March 2011, 2012, 2013 Small Group Leader, Medical Student Capstone Course, “MRSA”

August 2011, 2012 Small Group Leader, “Antibiotics for Internal Medicine Interns”

March-May 2012 Small Group Preceptor, Microbial Topics, Microbiology & Immunology Course for Medical Students

July 2020 Lecturer, Case Studies in COVID-19 elective course for Vanderbilt School of Medicine and Public Health students, “Pharmaceutical Approaches”

Other Teaching Activities:

April 2008 Vanderbilt University School of Medicine, Internal Medicine Resident Senior Talk, “Blood Culture: Friend or Foe?”

June 2010 Vanderbilt University School of Medicine, Infectious Diseases Journal Club; Discussion of “Initial Low-Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis is Nephrotoxic” (Cosgrove, et al. CID 2009)

September 2010 Vanderbilt University School of Medicine, Infectious Diseases Morbidity, Mortality, and Improvement Conference, “A Missed Diagnosis of Tuberculosis”

January 2011 Vanderbilt University School of Medicine, Infectious Diseases Journal Club; Discussion of “Rapid Molecular Detection of Tuberculosis and Rifampin Resistance” (Boehme, et al. NEJM 2010)

June 2011 Vanderbilt University School of Medicine, Infectious Diseases Grand Rounds “Fluoroquinolone Exposure and Clinical Outcomes in Tuberculosis”

February 2012 Vanderbilt University School of Medicine, Infectious Diseases Journal Club; Discussion of “Association Between Use of Statins and Mortality Among Patients Hospitalized with Laboratory-Confirmed Influenza Virus Infections” (Vandermeer, et al. JID 2012)

May 2012	Vanderbilt University School of Medicine, Infectious Diseases Grand Rounds “Drug Resistance, Fluoroquinolones, and Tuberculosis”
June 2013	Vanderbilt University School of Medicine, Infectious Diseases Grand Rounds “Refugee Health in Tennessee: Focus on Infectious Diseases”
May 2014, May 2015, April 2017, Feb. 2020	Vanderbilt University School of Medicine, Infectious Diseases Fellow Lecture “Zoonoses”
April 2015, Jan. 2017	Vanderbilt University School of Medicine, Pulmonary Fellow Lecture “Nontuberculous Mycobacterial Infections”
April 2015	Vanderbilt University School of Medicine, Infectious Diseases Grand Rounds “Tuberculosis in Durban, South Africa: Findings from a Large, Urban Cohort”
October 2016	Vanderbilt University School of Medicine, 2016 Vanderbilt Translational Research Forum “Fluoroquinolone Resistance in Patients with Multidrug-Resistant Tuberculosis”
November 2016	Vanderbilt University School of Medicine, Vanderbilt Tuberculosis Center Presentation “Acquired TB Drug Resistance: Updates After a Cape Town Adventure”
February 2017	Vanderbilt University School of Medicine, Infectious Diseases Grand Rounds “Acquired TB Drug Resistance: (More) Updates After a Cape Town Adventure”
Nov. 2018, Dec. 2020	Vanderbilt University School of Medicine, Pulmonary Fellow Lecture “Tuberculosis: Preventable, Curable, Yet Top Global Infectious Killer”
January 2020	Vanderbilt University School of Medicine, Infectious Diseases Grand Rounds “The Quick Pace of Change in Drug-Resistant Tuberculosis Treatment: Focus on South Africa”
May 2020	Assist International, Vanderbilt Institute for Global Health & Vanderbilt University Medical Center, Project ECHO COVID-19 Tele-Education Series for Healthcare Providers in LMICs, “What’s new in COVID-19? Treatment and Research Updates”
June 2020	CDC Foundation Advanced HIV Disease Global Webinar Series, Project ECHO, “Unintended Consequences of the COVID-19 Response on the TB Program”
August 2020	Vanderbilt University School of Medicine, Internal Medicine Resident Lecture “COVID-19 Treatment Update”

February 2021

Vanderbilt University School of Medicine, Internal Medicine
Resident Lecture “Tuberculosis”

ONGOING GRANT SUPPORT:

NIH/NIAID K08 AI106420

Start and end dates: August 1, 2014 – July 31, 2019 (No Cost Extension to July 31, 2021)

Project Title: Fluoroquinolone resistance in patients with multidrug-resistant tuberculosis

Total funding: \$162,341 Current Year Direct

Role of the applicant: Principal Investigator

Percent effort: 1%

U.S. Civilian Research and Development Foundation

Start and end dates: September 1, 2019 – August 31, 2021

Project Title: RePORT International and CFAR Cross-Consortia Study: Immune activation and dysglycemia in tuberculosis patients with and without HIV

Total funding: \$104,488 Current Year Direct

Role of the applicant: Co-Principal Investigator

Percent effort: 18%

NIH/NIAID R24 AI124872

Start and end dates: April 1, 2020 – March 31, 2021

Project Title: Harmonist: A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research Networks

Role of the applicant: Co-Investigator

Percent effort: 15%

U.S. Civilian Research and Development Foundation

Start and end dates: May 1, 2020 – April 30, 2022

Project Title: RePORT International Coordinating Center

Role of the applicant: Co-Investigator

Percent effort: 5%

U.S. Civilian Research and Development Foundation

Start and end dates: October 1, 2020 – October 1, 2023

Project Title: The RePORT South Africa Consortium

Role of the applicant: Co-Investigator

Percent effort: 10%

COMPLETED GRANT SUPPORT:

July 2012-May 2013

Ruth L. Kirschstein National Research Service Award, Vanderbilt Infection Pathogenesis and Epidemiology Research Training Grant, NIH T32 AI 07474-16

July 2012-May 2013

Vanderbilt Institute for Clinical and Translational Research (VICTR) pilot study award: Prediction rules for the optimal use of fluoroquinolones in people at risk for tuberculosis, VR4870, \$2000

July 2014

Vanderbilt Physician Scientist Development (VPSD) Program Award: Fluoroquinolone resistance in patients with multidrug-

resistant tuberculosis [replaced by NIH K08]

July 2019-Nov. 2020 U.S. Civilian Research and Development Foundation, RePORT International: Identifying Innovative Bacterial and Host-Mediated Biomarkers of Treatment Response to Tuberculosis Chemotherapy Co-Investigator

PUBLICATIONS AND PRESENTATIONS

Peer reviewed research articles (*corresponding author):

1. **van der Heijden YF**, Miller G, Wright PW, Shepherd BE, Daniels TL, Talbot TR. Clinical impact of blood cultures contaminated with coagulase-negative staphylococci at an academic medical center. *Infection Control and Hospital Epidemiology*. 2011 Jun; 32(6): 623-5. [no associated NIH funding]*
2. Maruri F, Sterling TR, Kaiga AW, Blackman A, **van der Heijden YF**, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant *Mycobacterium tuberculosis* and a proposed gyrase numbering system. *Journal of Antimicrobial Chemotherapy*. 2012 Apr; 67(4): 819-31. PMID: PMC3299416.
3. **van der Heijden YF**, Maruri F, Blackman A, May CS, Mitchel E, Holt E, Warkentin JV, Sterling TR. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. *International Journal of Tuberculosis and Lung Disease*. 2012 Sep; 16(9): 1162-7. PMID: PMC3981533.*
4. **van der Heijden YF**, Maruri F, Blackman A, Mitchel E, Shintani A, Eden S, Warkentin JV, Sterling TR. Fluoroquinolone susceptibility in *Mycobacterium tuberculosis* after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. *International Journal of Antimicrobial Agents*. 2013 Sep; 42(3): 232-7. PMID: PMC3780576.*
5. **van der Heijden YF**, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. A Comparison of Interview Methods to Ascertain Fluoroquinolone Exposure Before Tuberculosis Diagnosis. *Epidemiology and Infection*. 2015 Apr; 143(5): 960-5. PMID: PMC4352378.*
6. **van der Heijden YF**, Heerman WJ, McFadden S, Zhu Y, Patterson, B. Missed Opportunities for Tuberculosis Screening in Primary Care. *Journal of Pediatrics*. 2015 May; 166(5):1240-5. PMID: PMC4414729.*
7. Eilertson B, Maruri F, Blackman A, Guo Y, Herrera M, **van der Heijden Y**, Shyr Y, Sterling TR. A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in *Mycobacterium tuberculosis*. *Journal of Antimicrobial Chemotherapy*. 2016 Sep; 71(9): 2419-27. PMID: PMC4992850.
8. **van der Heijden YF**, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa M-YS, Sterling TR, Pym AS. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. *International Journal of Tuberculosis and Lung Disease*. 2017 Jun; 21(6): 670-6. PMID: PMC5536436.*

9. **van der Heijden YF**, Karim F, Chinappa T, Mufamadi G, Zako L, Shepherd BE, Maruri F, Moosa M-YS, Sterling TR, Pym AS. Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. *International Journal of Tuberculosis and Lung Disease*. 2018 Aug; 22(8): 871-8. PMID: PMC6064608.*
10. **van der Heijden YF**, Abdullah F, Andrade BB, Andrews JR, Christopher DJ, Croda J, Ewing H, Haas DW, Hatherill M, Horsburgh Jr CR, Mave V, Nakaya HI, Rolla V, Srinivasan S, Sugiyono RI, Ugarte-Gil C, Hamilton C. Building capacity for advances in tuberculosis research; Proceedings of the third RePORT International meeting. *Tuberculosis*. 2018 Dec; 113: 153-62. PMID: PMC6349374.
11. Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, **van der Heijden Y**, Wood R, Rustomjee R, Kana BD. Advances in the science of *Mycobacterium tuberculosis* transmission in HIV-endemic settings. *The Lancet Infectious Diseases*. 2019 Mar; 19(3): e65-e76. PMID: PMC6401310.
12. Khan PY, Yates TA, Warren RM, **van der Heijden YF**, Padayatchi N, Nardell EA, Moore DA, Mathema B, Gandhi NR, Eldholm V, Dheda K, Osman M, Hesselning A, Mizrahi V, Rustomjee R, Pym A. Transmission of drug-resistant tuberculosis in HIV-endemic settings. *The Lancet Infectious Diseases*. 2019 Mar; 19(3): e77-e88. PMID: PMC6474238.
13. **van der Heijden YF**, Hughes J, Dowdy DW, Streicher E, Chihota V, Jacobson KR, Warren R, Theron G. Overcoming limitations of tuberculosis information systems: researcher and clinician perspectives. *Public Health Action*. 2019 Sep; 9(3): 120-7. PMID: PMC6827492.*
14. Maruri F, Guo Y, Blackman A, **van der Heijden YF**, Rebeiro PF, Sterling TR. Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible *M. tuberculosis* isolates: a proposed threshold for identifying resistance. *Clinical Infectious Diseases*. 2020. Apr; doi: 10.1093/cid/ciaa496. [Epub ahead of print] PMID: 32348473.
15. Ndlovu LN, Peetluk L, Moodley S, Nhamoyebonde S, Ngoepe TA, Mazibuko M, Khan K, Karim F, Pym AS, Maruri F, Moosa MS, **van der Heijden YF**, Sterling TR, Leslie A. Increased neutrophil count and decreased neutrophil CD15 expression correlate with TB disease severity and treatment response irrespective of HIV co-infection. *Frontiers in Immunology*. 2020; 11:1872. PMID: PMC7485225.
16. Manful A, Waller L, Katz B, Cummins J, Warkentin J, Reagon B, Shaw-Kaikai J, Zhu Y, **van der Heijden YF**. Gaps in the Care Cascade for Screening and Treatment of Refugees with Tuberculosis Infection in Middle Tennessee: A Retrospective Cohort Study. *BMC Infectious Diseases*. 2020. Aug; 20(1): 592. PMID: PMC7418421.*
17. Blackman A, Morrison R, Maruri F, **van der Heijden Y**, Nochowicz C, Guo Y, Scholz M, Rustad T, Sherman D, Sterling T. Re-evaluation of a novel resistance mutation in eccC₅ of the ESX-5 secretion system in ofloxacin-resistant *Mycobacterium tuberculosis*. *Journal of Antimicrobial Chemotherapy*. 2020. Dec; doi: 10.1093/jac/dkaa507. [Epub ahead of print] PMID: 33367727.
18. Manesen MR, Mekler KA, Molobi TR, Tyiki AA, Madlavu MJ, Velen K, Charalambous S, **van der Heijden YF**. Data quality assessment of a South African electronic registry for drug-resistant tuberculosis, 2015-2016. *Public Health Action*. 2020. In Press.

Poster Presentations at Scientific Meetings (*chosen for oral presentation):

1. **van der Heijden YF**, Maruri F, Blackman A, May CS, Mitchel E, Holt E, Warkentin JV, Sterling TR. Fluoroquinolone Exposure Prior To Tuberculosis Diagnosis Is Associated With An Increased Risk Of Death. Vanderbilt University School of Medicine Research Forum. Nashville, TN. April 21, 2011.
2. **van der Heijden YF**, Maruri F, Blackman A, May CS, Mitchel E, Holt E, Warkentin JV, Sterling TR. Fluoroquinolone Exposure Prior To Tuberculosis Diagnosis Is Associated With An Increased Risk Of Death. American Thoracic Society International Conference, Abstract Number 16983. Denver, CO. May 15, 2011.
3. **van der Heijden YF**, Maruri F, Blackman A, Mitchel E, Shintani A, Eden S, Warkentin JV, Sterling TR. Older versus Newer Fluoroquinolones Prior to TB Diagnosis: No Effect on Fluoroquinolone MIC. International Union Against Tuberculosis and Lung Disease World Conference, Abstract Number PC-1237-30. Lille, France. October 30, 2011.
4. **van der Heijden YF**, Maruri F, Sterling TR, Kaiga AW, Blackman A, Mayer C, Cambau E, Aubry A. A Systematic Review of Gyrase Mutations Associated with Fluoroquinolone-Resistant *Mycobacterium tuberculosis* and a Proposed Gyrase Numbering System. American Thoracic Society International Conference, Abstract Number 33173. San Francisco, CA. May 21, 2012.
5. **van der Heijden YF**, Karim F, Parker G, Chinappa T, Mufamadi G, Zako L, Shepherd B, Sterling TR, Pym A. Decreased TB Recurrence After Introduction of ART in Durban, South Africa. Conference on Retroviruses and Opportunistic Infections, Abstract Number 830. Seattle, WA. February 24, 2015.
6. **van der Heijden YF**, Maruri F, Karim F, Parker G, Moosa Y, Chinappa T, Sterling TR, Pym A. Isoniazid Mono-Resistance is Associated with Increased Mortality in a Large Cohort of Tuberculosis Patients in Durban, South Africa. International Union Against Tuberculosis and Lung Disease World Conference, Abstract Number OA-466-06. Cape Town, South Africa. December 6, 2015.*
7. **van der Heijden YF**, Maruri F, Karim F, Mufamadi G, Moosa Y, Shepherd B, Sterling TR, Pym A. Factors Associated with Multiple Tuberculosis Recurrences Among HIV-uninfected Persons. International Union Against Tuberculosis and Lung Disease World Conference, Abstract Number PD-982-28. Liverpool, United Kingdom. October 28, 2016.
8. **van der Heijden YF**, Dunbar R, Dolby T, Shepherd B, Cox H, Dheda K, Sterling TR, Warren R. Differences in ascertainment of tuberculosis resistance according to four patient-matching strategies using programmatic laboratory data in South Africa. International Workshop on HIV and Hepatitis Observational Databases, Abstract Number 056. Fuengirola, Spain. March 23, 2018.
9. **van der Heijden YF**, Dunbar R, Dolby T, Shepherd B, Cox H, Dheda K, Sterling TR, Warren R. Emergence of tuberculosis drug resistance by different patient-matching strategies using laboratory data. International Union Against Tuberculosis and Lung Disease World Conference, Abstract Number SOA17-1174-27. The Hague, The Netherlands. October 27, 2018.*

10. **van der Heijden YF**, Karim F, Maruri F, Peetluk L, Moodley S, Mazibuko M, Khan K, Moosa M-Y, Sterling TR, Leslie A. High Proportion of Transient Hyperglycemia at Tuberculosis Diagnosis among People Living with and without HIV in South Africa. International Union Against Tuberculosis and Lung Disease World Conference, Abstract Number OA-24-647-23. Virtual Conference. October 23, 2020.*

Invited scientific lectures (Internal/Local):

- April, July 2013 Vanderbilt University, Undergraduate Course: Global Public Health MHS 202, Lecture, “Tuberculosis”
- April 2014 Tennessee Department of Health, 2014 World TB Day Symposium; Didactic presenter for Case: “MDR-TB: Asymptomatic Contact of an Abdominal TB Case”
- May 2018 Tennessee Department of Health, Invited Presentation “Tuberculosis in South Africa”
- November 2018 Tennessee Department of Health, Biostatistics Clinic Lecture “Emergence of Drug Resistance by Different Patient-Matching Strategies Using Laboratory Data”

Invited lectures and scientific meeting presentations (National):

- May 2012 Christian Community Health Fellowship Annual Conference, “Updates in the Treatment and Care of People Living with HIV in the US”

Invited lectures and scientific meeting presentations (International):

- February 2016 Desmond Tutu Tuberculosis Centre, Stellenbosch University, Academic Meeting “Fluoroquinolone Resistance in Patients with Multidrug-Resistant Tuberculosis”
- March 2016 Stellenbosch University, Division of Molecular Biology and Human Genetics, Academic Meeting, “Fluoroquinolone Resistance in Patients with Multidrug-Resistant Tuberculosis”
- June 2016 KwaZulu-Natal Research Institute for Tuberculosis and HIV, organizer and speaker, Research Capacity Building Workshop
- June 2018 The Aurum Institute, Lecture “Tuberculosis: From the Southeast USA to South Africa”
- June 2019 The Aurum Institute, Journal Club “Overcoming Limitations to Optimize Understanding of TB Epidemiology”
- July 2019 Stellenbosch University, Division of Molecular Biology and Human Genetics, Division Lecture “Overcoming Limitations to Optimize Understanding of TB Epidemiology”

November 2019 The Aurum Institute, Scientific Advisory Council Meeting “TB Treatment Studies”

Mentoring/career development lectures (Internal):

October 2014 Vanderbilt University School of Medicine, Grant Pacing Workshop Presentation